GAVRIL KERTESZ et Associés SRL
GAVRIL KERTESZ et Associés reported total assets of 758,202 € at the end of the 2025 financial year (annual accounts filed with the NBB on 31 May 2026).
The score of GAVRIL KERTESZ et Associés shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Accounts of the company itself (not consolidated).
The full file covers 2 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
GAVRIL KERTESZ et Associés's annual accounts
Filed annual accounts
- Year ended 30 Sep 2025filed on 31 May 2026
- Year ended 30 Sep 2024filed on 14 Apr 2025
GAVRIL KERTESZ et Associés's financial analysis
- Solvency72.9%sector median: 43.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of GAVRIL KERTESZ et Associés
GAVRIL KERTESZ et Associés's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0466.674.720
- VAT number
- BE0466674720
- Peppol
- Registered · 0208:0466674720 · as of 10 Nov 2026
- Legal form
- SRL
- Incorporated
- 09 Aug 1999
- Registered office
- 4537 Verlaine
- Latest accounts
- 2025 · filed on 31 May 2026
- Activity
- Wholesale of pharmaceutical and medical goods (NACE 46460)
GAVRIL KERTESZ et Associés (SRL) has been based in Verlaine since 1999, active in: wholesale of pharmaceutical and medical goods. For 2025, it reports a net profit of 171,008 € and equity of 552,795 €; its revenue is not published. Its solvency stands at 72.9%, above the median of its sector (43.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to GAVRIL KERTESZ et Associés
Companies in the same business, of comparable size and area, outside its group.
- PL Healthcare Wholesale of pharmaceutical and medical goods Villers-le-Bouillet · balance sheet 828,801 €
- Meditron Wholesale of pharmaceutical and medical goods Sint-Gillis-Waas · balance sheet 488,085 €
- Euro Medical Wholesale of pharmaceutical and medical goods Burdinne · balance sheet 807,168 €
- Paloma Curiosa Wholesale of pharmaceutical and medical goods Roeselare · balance sheet 710,783 €
- Phenox Wholesale of pharmaceutical and medical goods Overijse · balance sheet 887,046 €
- Uplifted Wholesale of pharmaceutical and medical goods Beringen · balance sheet 585,394 €
- Mobimed Wholesale of pharmaceutical and medical goods Roeselare · balance sheet 600,671 €
- ALL Products Wholesale of pharmaceutical and medical goods Aalst · balance sheet 972,749 €
Frequently asked questions about GAVRIL KERTESZ et Associés
What is the revenue of GAVRIL KERTESZ et Associés?
GAVRIL KERTESZ et Associés files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of GAVRIL KERTESZ et Associés?
In Belgium, the VAT number is the company number prefixed with BE: BE0466674720 for GAVRIL KERTESZ et Associés, if the company is VAT-registered. Its company number (CBE) is 0466.674.720.
Where is the registered office of GAVRIL KERTESZ et Associés?
According to the CBE register, the registered office of GAVRIL KERTESZ et Associés is in 4537 Verlaine.
What is the equity of GAVRIL KERTESZ et Associés?
At the close of the 2025 financial year, the equity of GAVRIL KERTESZ et Associés amounts to 552,795 €, a solvency of 72.9% of total assets.
Who manages GAVRIL KERTESZ et Associés?
The register lists 1 active mandates at GAVRIL KERTESZ et Associés. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of GAVRIL KERTESZ et Associés
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →